You can't fix what you don't measure, and you can't measure NAD+ the way you measure cholesterol. NAD+ is the most slippery analyte in clinical biochemistry — collected blood degrades NAD+ so rapidly that abnormal results show up within minutes of the draw unless the sample is flash-stabilized at the point of collection. The practitioner corpus is blunt about this: a "low NAD+" report from a standard lab is almost always a preservation artifact, not a real read on your intracellular pool. So the entire labs-that-matter chapter starts with a hard truth — you are not going to directly measure cellular NAD+. You are going to measure its downstream consequences and upstream depletion drivers, and you are going to triangulate.
What's actually happening at the cellular level
NAD+ is an intracellular signal from the mitochondria to the nucleus. When mitochondrial output drops — fewer electrons moving through the electron transport chain, less ATP per glucose, more electron leak as reactive oxygen species — the NAD+/NADH ratio collapses, sirtuins go quiet, PARP enzymes burn through what NAD+ remains trying to repair DNA damage, and the cell loses its energy-status signal to the nucleus. By age 60, NAD+ loss accelerates exponentially. The damage curve is steep.
The labs in this chapter map to three buckets:
- Upstream — what's depleting NAD+ (methylation status, B-vitamin cofactors, insulin resistance, sleep architecture)
- Midstream — proxy markers of mitochondrial function (lactate/pyruvate ratio, OAT organic acids, GDF-15, mtDNA copy number)
- Downstream — system-level resilience (HRV, fasting insulin/HOMA-IR, IGF-1, inflammatory load)
Most peptide clinics running NAD+ optimization use the midstream and downstream markers as their feedback signal. The upstream markers tell you what to fix before you even start dosing.
The labs that matter
| Marker | What it tells you | Reference range / threshold | Lagging or Leading | Pull cadence | Evidence tier |
|---|---|---|---|---|---|
| Lactate/pyruvate ratio (fasting) | Mitochondrial redox status — elevated ratio = electron transport chain dysfunction | Ratio >25 suggests dysfunction; <15 is healthy | Leading — shifts within weeks of mitochondrial intervention | Baseline, week 4, week 10 | Expert |
| NAD+/NADH ratio (whole blood, flash-stabilized) | Cellular energy metabolism efficiency — substrate-cited as the cleanest direct read available | Lab-specific; trend matters more than absolute | Leading — shifts within 2-4 weeks of NAD+ precursor or injection protocol | Baseline, week 6, week 10 | Expert |
| Organic Acids Test (urine OAT) | Citric acid cycle intermediates, methylation status, B-vitamin function | Per-marker thresholds (methylmalonic acid for B12, FIGLU for folate) | Leading on cofactor deficiency; lagging on cellular energy | Baseline, week 10 | Expert |
| Methylmalonic acid (urine or serum) | The most sensitive marker for functional B12 deficiency — substrate-cited as the gold standard | Elevated = B12 functionally low even if serum B12 looks fine | Leading | Baseline, repeat at week 8 if elevated | Clinical |
| Fasting insulin | Metabolic flexibility status — GATE for whether you can run the protocol | >8 mIU/L = STOP. Fix insulin resistance first | Leading | Baseline; non-negotiable | Clinical |
| HOMA-IR | (Fasting insulin × fasting glucose) / 405 — quantifies pancreatic workload | <1.0 = optimal, >2.0 = resistant | Leading | Baseline, week 8 | Clinical |
| HRV (rolling 30-day average) | Autonomic resilience — substrate frames this as mitochondrial output expressed at the system level | Trend matters more than absolute; personal baseline + 10-15% is the response signal | Leading — shifts within 2-3 weeks | Daily wearable, review weekly | Expert |
| GDF-15 (serum) | Mitochondrial stress biomarker — elevated when cells are running on damaged mitochondria | Lab reference; trending down = real response | Lagging — shifts over 8-12 weeks | Baseline, week 10 | Experimental → Expert |
| mtDNA copy number (whole blood) | Direct count of mitochondrial DNA per cell — proxy for mitochondrial mass | Lab-specific; trending up = biogenesis is happening | Lagging | Baseline, week 12 | Experimental |
| IGF-1 | Downstream of GH axis; cross-references with NAD+ protocol response | 150-250 ng/mL adult target | Leading | Baseline, week 8 | Clinical |
| hs-CRP | Inflammatory load — confounds every mitochondrial marker if elevated | <1.0 mg/L optimal | Lagging | Baseline, week 10 | Clinical |
| Humanin / MOTS-c (serum) | Mitochondrial-derived peptides — emerging biomarkers of mitochondrial integrity | [practitioner corpus thin on reference ranges — track and report] | Leading (theoretical) | Baseline, week 12 if available | Experimental |
When to pull what
Week 0 (baseline, before any compound): Fasting insulin, HOMA-IR, lactate/pyruvate, OAT (urine), methylmalonic acid, hs-CRP, IGF-1, HRV baseline (14-day rolling average from a wearable, not a one-off reading).
Week 4 (mid-Phase 1): Lactate/pyruvate ratio, HRV trend. This is your early response signal. If lactate/pyruvate hasn't moved and HRV is flat, the protocol isn't landing — recheck compliance, reconstitution, injection site, sleep.
Week 8: Fasting insulin, HOMA-IR, IGF-1, methylmalonic acid (if it was elevated at baseline).
Week 10-12 (end of intervention): Full re-pull. GDF-15 and mtDNA copy number show up here because they're lagging — they don't tell you anything useful at week 4.
The leading vs lagging distinction (critical)
Practitioner consensus on mitochondrial protocols: HRV and lactate/pyruvate are your leading edge. They will move within 2-4 weeks of a working protocol. If they don't move, the protocol isn't working — don't wait for the lagging markers to confirm a failure you could have caught early.
GDF-15, mtDNA copy number, IGF-1, hs-CRP are lagging. They confirm that real cellular restructuring has happened — biogenesis, reduced electron leak, reduced inflammatory tone — but they take 8-12 weeks to reflect what's actually changing inside the mitochondrion.
Fasting insulin is the gate, not a response marker. If yours is >8 mIU/L at baseline, the substrate is unambiguous — do not start GH secretagogues alongside the NAD+ protocol. Growth hormone antagonizes insulin. You'll push yourself deeper into metabolic dysfunction while thinking you're optimizing. Resolve insulin first, then layer in the NAD+ stack.
What's NOT happening at the labs level yet
- Direct intracellular NAD+ measurement that you can trust from a standard lab. It is not a real number unless the sample was flash-stabilized within seconds of the draw. Most lab reports labeled "NAD+" are degradation artifacts. Trend your downstream proxies instead.
- A single mitochondrial blood test. The substrate is explicit: "no single blood test measures mitochondrial health directly." Triangulate across the three buckets above.
- A clean response signal at week 2. Mitochondrial biogenesis is slow. Wearable HRV will show movement first, but the deeper markers need 8-12 weeks. Do not chase the protocol because the week-2 labs look flat — that's expected.
- GDF-15 in the normal range proving anything. A "normal" GDF-15 doesn't rule out mitochondrial dysfunction. A trending-down GDF-15 from an elevated baseline is the signal that matters.
- Standard physical bloodwork catching this. Standard CBC + CMP + lipid panels will miss everything in this chapter. You need to order these markers explicitly.
The labs describe what's happening at the cellular level. Track them. Adjust the protocol against the leading edge, not the lagging confirmation.